EUCTR2015-001824-43-GB进行中（未招募）1 期
A Phase 1b/2, multi-center, double-blind (principal investigators and study subjects blinded, sponsor unblinded), placebo-controlled, randomized, single-ascending dose study to assess the safety, pharmacokinetics, and pharmacodynamics of DS-1040B in subjects with acute ischemic stroke.
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Subjects have a clinical diagnosis of acute ischemic stroke (including lacunar stroke) supported by computed topography or magnetic resonance imaging to rule out alternative cause for presenting symptoms.
- •2. Men and women 18 years of age and older.
- •3. Subjects have stroke symptoms onset within 4.5 to 12 hours before initiation of study drug administration. For subjects with a wake-up stroke, symptoms onset time refers to the last time the subject was known to be well.
- •4. Subjects have a NIHSS score of >2 (Cohort 1-5).
- •4a. NIHSS score = 5 (Cohort 6).
- •5. In Cohort 6, subjects who have been treated or are anticipated to be
- •treated with IAT for index stroke, at the time of randomization, can be enrolled in the IAT subgroup.
- •6. Subjects (or their legally authorized representative-where applicable
- •and based on country-specific practice), must give written informed
- •consent to participate in the study prior to participating in any study related
- •procedures. A separate written informed consent is required for
- •collecting a blood sample for genotyping.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 76
排除标准
- •1.Cohort 1-5: Subjects have been treated or are anticipated to be treated with tissue plasminogen activator and/or endovascular thrombectomy during current stroke. Eligible subjects declining these treatments can be enrolled to this study.
- •1a. Cohort 6: subjects have been treated and/or are anticipated to be
- •treated with tPA during current stroke. Eligible subjects declining tPA
- •treatment can be enrolled to this study. Subjects have been treated or
- •anticipated to be treated with IAT can be enrolled.
- •2. Subjects have evidence of intracranial hemorrhage on noncontrast computed tomography (CT) (or magnetic resonance [MR]).
- •3. Subjects have symptoms of subarachnoid hemorrhage, even with normal CT.
- •4. Subjects have an Alberta Stroke Program Early CT Score (ASPECTS) < 6.
- •5. Subjects have prior non-traumatic intracranial haemorrhage(excluding microhemorrahages observed in imaging).
- •6. Subjects have known arteriovenous malformation or aneurysm.
- •7. Subjects have evidence of active bleeding.
- •8. Subjects have platelet count < 100,000.
- •9. Subjects have INR>1.7.
- •10. Subjects have used unfractionated heparin within 24 hours prior to treatment and have an elevated partial thromboplastin time.
- •11. Subjects have used a nonvitamin K antagonist oral anticoagulant such as dabigatran, rivaroxaban, apixaban, or other factor Xa inhibitors within 24 hours prior to treatment.
- •12. Subjects have used fondaparinux or low molecular weight heparin at an anticoagulation dose within 24 hours prior to treatment.
- •13. Subjects with anticipated use of an anticoagulation dose of heparin,
- •or fondaparinux or low molecular weight heparin, or nonvitamin K
- •antagonist oral anticoagulant such as dabigatran, rivaroxaban, apixaban,
- •or other factor Xa inhibitors within 48 hours after completion of study
- •drug treatment . Low dose heparin or low molecular weight heparin at a
- •preventive dose are allowed from 24 hours after treatment completion
- •and after confirmation of no intracranial bleeding on the 24 hours repeat
- •brain imaging. In Cohort 6, heparin treatment associated with IAT is
- •14. Subjects have blood pressure>185/110 mmHg, or require aggressive medication to maintain blood pressure below this limit (routine medical treatment is allowed to lower the blood pressure below this limit).
- •15. Subjects have had intracranial surgery, clinically significant head trauma (in the opinion of Principal Investigator), Alteplase treatment, or a previous stroke within 1 month.
- •16. Subjects have had major surgery within 14 days.
- •17. Subjects have had gastrointestinal or genitourinary bleeding in the last 21 days.
- •18. Subjects have had a lumbar puncture (or epidural steroid injection) within 14 days.
- •19. Subjects have a preexisting disability classified by mRS>2.
- •20. Subjects have an estimated glomerular filtration rate (using Modification of Diet in Renal Disease equation)<60 mL/min/1.73 m2.
- •21. Subjects have baseline hemoglobin<10.5 g/dL.
- •22. Subjects have a positive pregnancy test. Serum or urine pregnancy
- •tests will be performed (according to site-specific practice) in women of
- •childbearing potential (childbearing potential is assumed in women up to
- •55 years of age).
- •23. Subject is currently participating in another investigational study or has participated in an investigational drug study within 30 days or 5 half-lives of that investigational drug prior to administration of the study drug.
- •24. Subject is an employee or an immediate family member of an employee of the Sponsor, the CRO
研究者
相似试验
进行中（未招募）
1 期
A Phase 1b/2 study to assess the safety, pharmacokinetics, and pharmacodynamics of DS-1040B in subjects with acute ischemic stroke.EUCTR2015-001824-43-CZDaiichi Sankyo, Inc.150
进行中（未招募）
1 期
A Phase 1b/2 study to assess the safety, pharmacokinetics, and pharmacodynamics of DS-1040B in subjects with acute ischemic stroke.DS-1040b is an inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor (TAFIa) intended to be used for the treatment of thrombotic diseases including acute ischemic stroke (AIS).MedDRA version: 19.0 Level: LLT Classification code 10055221 Term: Ischemic stroke System Organ Class: 100000004852EUCTR2015-001824-43-ESDaiichi Sankyo, Inc.96
进行中（未招募）
1 期
A Phase 1b/2 study to assess the safety, pharmacokinetics, and pharmacodynamics of DS-1040B in subjects with acute ischemic stroke.DS-1040b is an inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor (TAFIa) intended to be used for the treatment of thrombotic diseases including acute ischemic stroke (AIS).EUCTR2015-001824-43-FRDaiichi Sankyo Development Ltd96
进行中（未招募）
1 期
A Phase 1b/2 study to assess the safety, pharmacokinetics, and pharmacodynamics of DS-1040B in subjects with acute ischemic stroke.DS-1040b is an inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor (TAFIa) intended to be used for the treatment of thrombotic diseases including acute ischemic stroke (AIS).MedDRA version: 19.1Level: LLTClassification code 10055221Term: Ischemic strokeSystem Organ Class: 100000004852EUCTR2015-001824-43-ITDaiichi Sankyo, Inc.96
进行中（未招募）
1 期
A Phase 1b/2 study to assess the safety, pharmacokinetics, and pharmacodynamics of DS-1040B in subjects with acute ischemic stroke.DS-1040b is an inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor (TAFIa) intended to be used for the treatment of thrombotic diseases including acute ischemic stroke (AIS).MedDRA version: 20.1 Level: LLT Classification code 10055221 Term: Ischemic stroke System Organ Class: 100000004852EUCTR2015-001824-43-SKDaiichi Sankyo, Inc.96